Literature DB >> 16816845

A clinical drug library screen identifies astemizole as an antimalarial agent.

Curtis R Chong1, Xiaochun Chen, Lirong Shi, Jun O Liu, David J Sullivan.   

Abstract

The high cost and protracted time line of new drug discovery are major roadblocks to creating therapies for neglected diseases. To accelerate drug discovery we created a library of 2,687 existing drugs and screened for inhibitors of the human malaria parasite Plasmodium falciparum. The antihistamine astemizole and its principal human metabolite are promising new inhibitors of chloroquine-sensitive and multidrug-resistant parasites, and they show efficacy in two mouse models of malaria.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16816845     DOI: 10.1038/nchembio806

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN: 1552-4450            Impact factor:   15.040


  116 in total

Review 1.  Induced pluripotent stem cells--opportunities for disease modelling and drug discovery.

Authors:  Marica Grskovic; Ashkan Javaherian; Berta Strulovici; George Q Daley
Journal:  Nat Rev Drug Discov       Date:  2011-11-11       Impact factor: 84.694

2.  Chemical screen identifies FDA-approved drugs and target pathways that induce precocious pancreatic endocrine differentiation.

Authors:  Meritxell Rovira; Wei Huang; Shamila Yusuff; Joong Sup Shim; Anthony A Ferrante; Jun O Liu; Michael J Parsons
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-14       Impact factor: 11.205

Review 3.  Computational and Practical Aspects of Drug Repositioning.

Authors:  Tudor I Oprea; John P Overington
Journal:  Assay Drug Dev Technol       Date:  2015 Jul-Aug       Impact factor: 1.738

Review 4.  Malaria biology and disease pathogenesis: insights for new treatments.

Authors:  Louis H Miller; Hans C Ackerman; Xin-zhuan Su; Thomas E Wellems
Journal:  Nat Med       Date:  2013-02-06       Impact factor: 53.440

5.  Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells.

Authors:  Su Mi Choi; Yonghak Kim; Joong Sup Shim; Joon Tae Park; Rui-Hong Wang; Steven D Leach; Jun O Liu; Chuxia Deng; Zhaohui Ye; Yoon-Young Jang
Journal:  Hepatology       Date:  2013-06       Impact factor: 17.425

Review 6.  Chemical genomics for studying parasite gene function and interaction.

Authors:  Jian Li; Jing Yuan; Ken Chih-Chien Cheng; James Inglese; Xin-zhuan Su
Journal:  Trends Parasitol       Date:  2013-11-09

7.  Hirschsprung-like disease is exacerbated by reduced de novo GMP synthesis.

Authors:  Jonathan I Lake; Olga A Tusheva; Brittany L Graham; Robert O Heuckeroth
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

8.  Pyrrolidine dithiocarbamate and diethyldithiocarbamate are active against growing and nongrowing persister Mycobacterium tuberculosis.

Authors:  Sean T Byrne; Peihua Gu; Jiangbing Zhou; Steven M Denkin; Curtis Chong; David Sullivan; Jun O Liu; Ying Zhang
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

9.  Cysteinyl leukotrienes as novel host factors facilitating Cryptococcus neoformans penetration into the brain.

Authors:  Longkun Zhu; Ravi Maruvada; Adam Sapirstein; Marc Peters-Golden; Kwang Sik Kim
Journal:  Cell Microbiol       Date:  2016-09-25       Impact factor: 3.715

10.  Discovery of novel antimalarial compounds enabled by QSAR-based virtual screening.

Authors:  Liying Zhang; Denis Fourches; Alexander Sedykh; Hao Zhu; Alexander Golbraikh; Sean Ekins; Julie Clark; Michele C Connelly; Martina Sigal; Dena Hodges; Armand Guiguemde; R Kiplin Guy; Alexander Tropsha
Journal:  J Chem Inf Model       Date:  2013-01-23       Impact factor: 4.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.